Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab.

Asia-Pacific journal of clinical oncology - 1 Aug 2022

Yamamoto Shumpei, Fukushima Hiroshi, Fukuda Shohei, Uehara Sho, Yasuda Yosuke, Tanaka Hajime, Yoshida Soichiro, Yokoyama Minato, Matsuoka Yoh, Fujii Yasuhisa

Abstract excerpt

AIM: We aimed to explore the association between cancer cachexia phenotypes in the early phase of treatment induction and the prognosis of advanced urothelial cancer (aUC) patients receiving pembrolizumab. METHODS: This retrospective study included 31 aUC patients treated with pembrolizumab as a second- or later-line therapy. Patients were categorized into three early cancer cachexia phenotypes by changes in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cachexia

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Transitional Cell

Share to Phenotype

Source

Identifiers

PMID: 34811871
DOI: 10.1111/ajco.13666

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab.PMID 34811871Read ↗

Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer.Semantic proximity Read ↗

Anatomical dynamics define cancer cachexia subtypes and identify systemic inflammation as a marker of lethal wastingSemantic proximity Read ↗

Characterization of pretreatment cachexia through cytokine and nutritional analysis in lung cancer: the Marató cohortSemantic proximity Read ↗

New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss.Semantic proximity Read ↗

Low skeletal muscle radiodensity predicts response to avelumab maintenance treatment in patients with metastatic urothelial carcinomaSemantic proximity Read ↗

Cancer-related fatigue: definitions and clinical subtypes.Semantic proximity Read ↗

Comparison of the Efficacy of Enfortumab Vedotin between patients with Metastatic Urothelial Carcinoma who were treated with Avelumab or Pembrolizumab: Real-World Data from a Multi-Institutional Study in JapanSemantic proximity Read ↗

Separating anorexia -dependent and -independent effects in cancer cachexiaSemantic proximity Read ↗

Photobiomodulation Therapy Moderates Cancer Cachexia-associated Muscle wasting through Activating PI3K/AKT/FoxO3a Pathway succinct title: PBMT Alleviates Muscle Wasting via PI3K/AKT/FoxO3a PathwaySemantic proximity Read ↗

Biomarkers for cancer cachexia: is there also a genetic component to cachexia?Semantic proximity Read ↗

Role of cachexia in advanced non-small cell lung cancer patients treated with EGFR-TKIS.Semantic proximity Read ↗

Clinical classification of cancer cachexia: phenotypic correlates in human skeletal muscle.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.